SCHEMBL22358296

SCHEMBL22358296

O=C(NCC(=O)N1CCN(C(=O)O)CC1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
RAB9A P51151 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.66
PREP P48147 2/20 0.52
DPP4 P27487 1/20 0.52
FAP Q12884 1/20 0.52
KDM4E B2RXH2 1/20 0.51
HTT P42858 1/20 0.51
P2RY12 Q9H244 1/20 0.51
GAA P10253 2/20 0.50
DPP7 Q9UHL4 1/20 0.50
LDHA P00338 1/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.49
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1442608 0.89 RAB9A (0.70) KMT2ARAB9ASMN1; SMN2PREPDPP4
SCHEMBL20924642 0.88 KMT2A (0.65) KMT2ARAB9ASMN1; SMN2PREPDPP4
SCHEMBL4753506 0.88 KMT2A (0.58) KMT2ARAB9ASMN1; SMN2KDM4EP2RY12
SCHEMBL3275319 0.87 RAB9A (0.68) KMT2ARAB9ASMN1; SMN2PREPDPP4
SCHEMBL14335466 0.84 SMN1; SMN2 (0.63) KMT2ARAB9ASMN1; SMN2KDM4EHTT
SCHEMBL22122851 0.84 SMN1; SMN2 (0.63) KMT2ARAB9ASMN1; SMN2PREPDPP4
SCHEMBL3861151 0.84 KMT2A (0.61) KMT2ARAB9ASMN1; SMN2POLBMEN1
SCHEMBL20924617 0.83 SMN1; SMN2 (0.61) KMT2ARAB9ASMN1; SMN2PREPDPP4
SCHEMBL4755200 0.83 SPHK2 (0.53) KMT2ARAB9ASMN1; SMN2KDM4EHTT
SCHEMBL1222690 0.83 KMT2A (0.60) KMT2ARAB9ASMN1; SMN2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 KMT2A 2479/4885RAB9A 2129/4885SMN1; SMN2 13/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 KMT2A 2479/4885RAB9A 2129/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.